2044-5385

Blood Cancer Journal

Springer Science and Business Media LLC

View prefix report (10.1038)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1316 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1316 DOIs
2

Attach ORCID iDs across 690 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact690 DOIs
3

Deposit reference lists for 86 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact86 DOIs

DOIs for this ISSN

Showing the top 5 of 2156 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Distribution and levels of cell surface expression of CD33 a… (10.1038/bcj.2014.39)
Abstract ORCID
125.05 316
2 Practice-relevant revision of IPSET-thrombosis based on 1019… (10.1038/bcj.2015.94)
Abstract ORCID
119.10 240
3 Erratum: The cellular immune system in myelomagenesis: NK ce… (10.1038/bcj.2015.49)
Abstract References ORCID
113.89 32
4 High prevalence of oncogenic MYD88 and CD79B mutations in di… (10.1038/bcj.2013.28)
Abstract ORCID
111.90 172
5 Long-term complications and side effects after allogeneic he… (10.1038/bcj.2011.14)
Abstract ORCID
111.39 168
6 Identification of Toyocamycin, an agent cytotoxic for multip… (10.1038/bcj.2012.26)
Abstract ORCID
109.79 156
7 Translocations at 8q24 juxtapose MYC with genes that harbor… (10.1038/bcj.2014.13)
Abstract ORCID
108.22 145
8 Erratum: Chronic myelomonocytic leukemia in younger patients… (10.1038/bcj.2015.9)
Abstract References ORCID
107.35 26
9 Corticosteroids do not influence the efficacy and kinetics o… (10.1038/s41408-020-0280-y)
Abstract ORCID
107.31 139
10 CD19-negative relapse of pediatric B-cell precursor acute ly… (10.1038/s41408-017-0023-x)
Abstract ORCID
106.03 131
11 Long-term survival in multiple myeloma is associated with a… (10.1038/bcj.2013.34)
Abstract ORCID
104.32 121
12 Pomalidomide: the new immunomodulatory agent for the treatme… (10.1038/bcj.2013.38)
Abstract ORCID
104.32 121
13 PD-1 expression defines two distinct T-cell sub-populations… (10.1038/bcj.2015.1)
Abstract ORCID
103.96 119
14 Myeloma cells suppress osteoblasts through sclerostin secret… (10.1038/bcj.2011.22)
Abstract ORCID
103.41 116
15 The glutathione synthesis inhibitor buthionine sulfoximine s… (10.1038/bcj.2014.45)
Abstract ORCID
102.85 113
16 A Phase 1 study of the novel gamma-secretase inhibitor PF-03… (10.1038/bcj.2015.80)
Abstract ORCID
102.46 111
17 The role of epigenetics in the biology of multiple myeloma (10.1038/bcj.2014.29)
Abstract ORCID
101.87 108
18 Clinical and molecular characterization of early T-cell prec… (10.1038/bcj.2011.49)
Abstract ORCID
100.85 103
19 The t(4;14) translocation and FGFR3 overexpression in multip… (10.1038/bcj.2012.37)
Abstract ORCID
100.43 101
20 A novel STAT inhibitor, OPB-31121, has a significant antitum… (10.1038/bcj.2013.63)
Abstract ORCID
100.43 101
21 Cardiac complications in relapsed and refractory multiple my… (10.1038/bcj.2014.93)
Abstract ORCID
100.43 101
22 Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment… (10.1038/bcj.2011.43)
Abstract ORCID
100.22 100
23 Markedly improved outcomes and acceptable toxicity in adoles… (10.1038/bcj.2014.72)
Abstract ORCID
99.78 98
24 Comorbidity as a prognostic variable in multiple myeloma: co… (10.1038/bcj.2011.34)
Abstract ORCID
99.56 97
25 Clonal hematopoiesis in patients with rheumatoid arthritis (10.1038/s41408-018-0107-2)
Abstract ORCID
99.56 97
26 Encouraging impact of doxycycline on early mortality in card… (10.1038/bcj.2017.26)
Abstract ORCID
99.11 95
27 Clinical features and outcomes of extramedullary myeloid sar… (10.1038/bcj.2017.79)
Abstract ORCID
99.11 95
28 Reduced TET2 function leads to T-cell lymphoma with follicul… (10.1038/bcj.2014.83)
Abstract ORCID
98.89 94
29 Upregulation of TET activity with ascorbic acid induces epig… (10.1038/bcj.2017.65)
Abstract ORCID
98.19 91
30 The oral HDAC inhibitor pracinostat (SB939) is efficacious a… (10.1038/bcj.2012.14)
Abstract ORCID
97.71 89
31 Long-term follow-up of serum immunoglobulin levels in blinat… (10.1038/bcj.2014.64)
Abstract ORCID
96.98 86
32 The therapeutic human CD38 antibody daratumumab improves the… (10.1038/bcj.2011.42)
Abstract ORCID
95.95 82
33 MicroRNA signatures in B-cell lymphomas (10.1038/bcj.2012.1)
Abstract ORCID
95.69 81
34 Dynamics of ASXL1 mutation and other associated genetic alte… (10.1038/bcj.2013.74)
Abstract ORCID
95.69 81
35 Lipid raft-mediated Akt signaling as a therapeutic target in… (10.1038/bcj.2013.15)
Abstract ORCID
95.42 80
36 Rationally engineered nanoparticles target multiple myeloma… (10.1038/bcj.2012.10)
Abstract ORCID
95.15 79
37 Immunomodulatory molecule PD-L1 is expressed on malignant pl… (10.1038/bcj.2015.7)
Abstract ORCID
95.15 79
38 Validation of the differential prognostic impact of type 1/t… (10.1038/bcj.2015.90)
Abstract ORCID
95.15 79
39 Regulatory B cell-myeloma cell interaction confers immunosup… (10.1038/bcj.2017.24)
Abstract ORCID
94.60 77
40 Role of stromal cell-mediated Notch signaling in CLL resista… (10.1038/bcj.2012.17)
Abstract ORCID
94.32 76
41 An open-label phase I dose-finding study of APR-246 in hemat… (10.1038/bcj.2016.60)
Abstract ORCID
93.75 74
42 The expression pattern of small nucleolar and small Cajal bo… (10.1038/bcj.2012.41)
Abstract ORCID
93.46 73
43 Flow cytometry based monocyte subset analysis accurately dis… (10.1038/bcj.2017.66)
Abstract ORCID
93.46 73
44 Redeployment-based drug screening identifies the anti-helmin… (10.1038/bcj.2011.38)
Abstract ORCID
93.17 72
45 Defining consensus leukemia-associated immunophenotypes for… (10.1038/bcj.2013.27)
Abstract ORCID
92.87 71
46 Hypoxia promotes stem cell-like phenotype in multiple myelom… (10.1038/bcj.2014.82)
Abstract ORCID
92.25 69
47 Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cy… (10.1038/bcj.2012.5)
Abstract ORCID
91.94 68
48 Antileukemic activity of the HSP70 inhibitor pifithrin-μ in… (10.1038/bcj.2011.28)
Abstract ORCID
91.63 67
49 Deregulated WNT signaling in childhood T-cell acute lymphobl… (10.1038/bcj.2014.12)
Abstract ORCID
90.31 63
50 Discovery and characterization of LY2784544, a small-molecul… (10.1038/bcj.2013.6)
Abstract ORCID
89.62 61